Work

318eP Therapeutic outcomes of PD-1 vs PD-L1 inhibitors in metastatic colorectal cancer: A meta-analysis of survival and safety

Year: 2025

Type: review

Study designs: Systematic Review, Meta-Analysis

Abstract: Immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 have revolutionized the treatment of multiple solid tumors, but their relative efficacy in metastatic colorectal cancer (mCRC) remains unclear. Therefore, this study aims to compare the survival outcomes and safety of PD-1 versus PD-L1 inhibitors in mCRC using data from randomized controlled trials (RCTs).

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101517